Dermatology Reports最新文献

{"title":"The efficacy of a bioactive moisturizer in mitigating side effects of acne therapies: a randomized, investigator-blind, split-face trial.","authors":"Jidapa Triwatcharikorn, Supanee Techamontrikul, Natnicha Ngamdumrongkiat, Pawinee Rerknimitr","doi":"10.4081/dr.2026.10491","DOIUrl":"https://doi.org/10.4081/dr.2026.10491","url":null,"abstract":"<p><p>Acne treatments often cause mucocutaneous side effects. This study compared a bioactive moisturizer (containing 4-t-butylcyclohexanol, licochalcone A, ceramide, and panthenol) with a traditional moisturizer in Asian patients using adapalene/benzoyl peroxide gel or oral isotretinoin. Forty participants applied each moisturizer to one side of the face. Assessments at weeks 0, 2, and 4 included hydration, trans-epidermal water loss (TEWL), pH, erythema, acne lesion counts, Investigator Global Evaluation of Acne (IGEA), and patient satisfaction. Hydration increased on both sides, with greater improvement from the bioactive moisturizer (p=0.001). TEWL increased more with the traditional moisturizer; skin pH decreased on both sides. Acne lesions decreased equally. Both moisturizers reduced burning sensations, but dryness scores were higher with the traditional product (p=0.021). Patient satisfaction was significantly higher for the bioactive side (p=0.004). The bioactive moisturizer significantly improves hydration and reduces dryness, supporting its role as an adjunct to acne therapy.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147527368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Condyloma acuminata prevalence, clinical characteristics, and associated malignancies in Saudi patients at a tertiary care center.","authors":"Yazeed Abdullah Alowairdhi, Mishari Tariq Alrubaiaan, Sarah Alrashid, Dana Alessa","doi":"10.4081/dr.2026.10465","DOIUrl":"https://doi.org/10.4081/dr.2026.10465","url":null,"abstract":"<p><p>Condyloma acuminata (CA) are benign anogenital warts caused by the human papillomavirus (HPV). Worldwide, HPV is the most common sexually transmitted disease (STD). Data from Saudi Arabia (SA) remains limited. This study aims to assess CA prevalence, clinical characteristics, co-existing STDs, fertility issues, and malignancies at the tertiary care center King Abdulaziz Medical City (KAMC), Riyadh, SA. A total of 118 patients diagnosed with CA were included. RStudio (version 2024.9.1.394, Boston, MA, USA) with R version 4.4.2. was utilized for statistical analysis. Among 15,016 patients attending the Dermatology Department during the study period, 118 were diagnosed with CA, constituting a prevalence of 0.79%. The majority of patients were male (n=69; 58.5%), with a median age of 33 years at the time of diagnosis. Perianal (n=40; 33.9%) and vulvar (n=39; 33.1%) regions were the most affected sites. Smoking (n=30; 25.4%), extramarital sexual activity (n=5; 8.8%), and abnormal Pap smear results (n=6; 5.7%) were significant findings. Immunodeficiency was noted in 3 patients (2.5%), and HPV vaccination status was low (n=6; 5.7%). Anogenital warts were found in 115 patients (97.5%), with Buschke-Löwenstein tumors in 3 patients (2.5%). Infertility was reported in 10 patients (17.2%); the majority had primary infertility (n=8; 80.0%). HPV vaccination, awareness, and prevention strategies are necessary to reduce CA burden and complications.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147510193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does the response to bimekizumab vary according to previous therapy with methotrexate<i> versus </i>cyclosporine?","authors":"Ilaria Salvi, Alexandra M G Brunasso, Franco Castelli, Andrea Michelerio, Paolo Pella, Marco Rubatto, Paolo Dapavo, Emanuele Cozzani, Martina Burlando","doi":"10.4081/dr.2026.10236","DOIUrl":"https://doi.org/10.4081/dr.2026.10236","url":null,"abstract":"<p><p>According to the Italian Medicines Agency (AIFA) guidelines, patients with moderate-to-severe psoriasis can access biological therapies in case of treatment failure or contraindication to at least one conventional systemic treatment. However, no studies have been conducted to investigate the potential influence of previous conventional systemic treatments on the efficacy of subsequently prescribed biologics. The purpose of this study was to evaluate whether patients treated with bimekizumab, a monoclonal anti-interleukin (IL)-17A/F drug, achieve Psoriasis Area and Severity Index (PASI) 90 at different times based on prior use of cyclosporine or methotrexate. Fifty-four patients were enrolled in this study; 29 had previously been treated with methotrexate and 25 with cyclosporine. There was a statistically significant difference in efficacy (measured by mean PASI score) at week 4 (p<0.01), with patients treated with methotrexate responding faster to bimekizumab. Females previously on treatment with cyclosporine responded better and faster, followed by females on methotrexate and then men on methotrexate. Men on cyclosporine showed a later response to bimekizumab. Our study confirmed that bimekizumab is a fast and effective biologic treatment for psoriasis. Patients previously treated with methotrexate responded faster to bimekizumab than those formerly treated with cyclosporine.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147484918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of severe dysplastic nevus (high-grade dysplasia): Italian recommendations for good clinical practice.","authors":"Cesare Massone, Giuseppe Argenziano, Carlo Cota, Gerardo Ferrara, Daniela Massi, Francesco Cusano, Maria Fino, Zuzana Mitrova, Rosella Saulle","doi":"10.4081/dr.2026.10672","DOIUrl":"https://doi.org/10.4081/dr.2026.10672","url":null,"abstract":"&lt;p&gt;&lt;p&gt;\"Dysplastic nevus\" (DN) is a histopathological term used to describe nevi with cytological atypia and architectural disorder. With the 2018 World Health Organization (WHO) classification, the grading system for atypia/dysplasia was simplified into two categories: low-grade dysplasia and high-grade dysplasia (severely atypical dysplastic nevus [SDN]); this classification is currently in use, and its criteria are applied by pathologists for the diagnosis of DN. Actually, there are currently no definitive guidelines for managing patients with DN. This lack of clear direction has historically led many specialists, both dermatologists and others, to perform or request a further widening of a lesion diagnosed as an SDN, even when it has already been completely excised, effectively treating it as a melanoma in situ (MIS). This tendency leads to a significant increase in the number of surgical procedures, consequently lengthening dermatological surgery waiting lists. Therefore, reducing the number of inappropriate widenings would have a strong impact on shortening these waiting lists, in addition to the physical and psychological impact a second procedure has on the individual patient. Moreover, the management of histologically severe DN has alternatives to widening because dermatologists can opt for observation (digital monitoring). The Italian National Center for Clinical Governance and Healthcare Excellence (CNCG) of the Istituto Superiore di Sanità (ISS) identified the scientific Italian Association of Hospital Dermatologists (ADOI) as the lead organization for the recommendations for good clinical practice on the management of SDN. Further, twelve scientific societies were involved. A systematic literature search was conducted on the following databases: Cochrane Library, MEDLINE, and Embase up to November 27, 2024. Only two retrospective, monocentric observational studies were considered eligible for the study because they had outcome data for both re-excised and observed patients with the specific histological diagnosis of severe atypia and negative margins, and one relevant systematic review. A GRADE-based assessment was conducted using a narrative summary of findings. The quality of evidence was rated as very low, based on the results from the two non-randomized studies: 0 events among 213 observed patients and 0 events among 101 re-excised patients (total n=314). The available data suggest that observation alone may be a safe alternative to re-excision. The omission of re-excision for DN with negative margins does not appear to increase the subsequent risk of melanoma. The Expert Panel unanimously judged the desirable effect of re-excision in reducing melanoma occurrence to be negligible when compared to observation alone. After collegial discussion, the Expert Panel's judgment on the question, \"In patients with a histological diagnosis of a completely excised high-grade DN (with negative margins), is re-excision of the surgical site more","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147484901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Free access to medications for scabies treatment in Italy: a call to action and the need to evaluate its clinical and epidemiological impact.","authors":"Corrado Zengarini, Martina Mussi, Iria Neri, Valeria Gaspari, Bianca Maria Piraccini, Giulia Rech, Salvatore Domenico Infusino, Michela Magnano, Laura Atzori, Riccardo Balestri","doi":"10.4081/dr.2026.10323","DOIUrl":"https://doi.org/10.4081/dr.2026.10323","url":null,"abstract":"<p><p>Dear Editor, The escalating spread of scabies, caused by the Sarcoptes scabiei mite, is a pressing and worrisome public health concern, with increasing worldwide incidence every year and frequent outbreaks, making it not only an Italian problem but a global one. The World Health Organization (WHO) has identified several key actions to control scabies, the most significant being the provision of funded therapies and their integration into universal health coverage programs. [...].</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147472419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frontal fibrosing alopecia and lichen planopilaris: epidemiology, treatment, and remission rate (2014-2024).","authors":"Yahya Argobi, Faris I Alasiri, Mohammad Azlan Omar","doi":"10.4081/dr.2026.10475","DOIUrl":"https://doi.org/10.4081/dr.2026.10475","url":null,"abstract":"<p><p>Frontal fibrosing alopecia (FFA) and lichen planopilaris (LPP) are cicatricial alopecia with overlapping but distinct epidemiological, clinical, and therapeutic features. This study evaluates their epidemiological and clinical characteristics, treatment approaches, and one-year remission rates. This retrospective cohort study was conducted at Holy Family Hospital, Karachi, Pakistan. Data from electronic records included demographics, clinical presentations, histology, treatments, outcomes, and follow-up. Patients of all ages and genders diagnosed with LPP or FFA between January 2014 and December 2024, with a minimum one-year follow-up, were included. LPP patients had a higher mean age at onset (53.1±9.42 years) than FFA patients (45.8±10.4 years; p=0.02). Scalp involvement was more common in LPP (95.9%), while body involvement was higher in FFA (85.7%; p<0.001). FFA patients had more symptoms, whereas LPP was often asymptomatic (p<0.001). Remission rates were similar at 12 months, but FFA showed higher long-term remission (59.0% vs. 39.0%; p=0.004). FFA patients sustained remission (55.7% vs. 23.4%; p<0.001), while LPP had more partial or no responses. This study highlighted key differences in demographics, clinical features, and treatments between FFA and LPP, with similarities in diagnostic delays and treatment approaches. Variations were noted in the age of onset, symptoms, clinical presentation, and outcomes.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147472373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The McGregor flap for lower eyelid defect reconstruction.","authors":"Andrea Paradisi, Irina Ciobotariu, Massimo Rocchetti","doi":"10.4081/dr.2026.10517","DOIUrl":"https://doi.org/10.4081/dr.2026.10517","url":null,"abstract":"<p><p>A 58-year-old Caucasian male presented with a 1.6×1 cm nodular lesion on the right lower eyelid, clinically diagnosed as basal cell carcinoma. Surgical excision was planned. How would you remove this lesion? [...].</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147431487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum ferritin and hair iron content in correlation to hair diameter and density: a case-control study.","authors":"Arlha Aporia Debinta, Windy Keumala Budianti, Andira Hardjodipuro, Sri Linuwih Menaldi, Dian Kusuma Dewi, Lili Legiawati, Yudo Irawan, Inge Ade Krisanti, Shannaz Nadia Yusharyahya","doi":"10.4081/dr.2026.10109","DOIUrl":"https://doi.org/10.4081/dr.2026.10109","url":null,"abstract":"<p><p>Androgenetic alopecia (AGA) is the most common non-scarring hair loss disorder in men due to susceptibility to testosterone. AGA causes cosmetic disturbances that affect confidence and quality of life. The correlation between low ferritin serum levels and AGA has been sufficiently proven in women but not in men. Thus, this study evaluated this correlation in Indonesian men. This case-control study included 33 men with AGA and 33 non-alopecia controls. Serum ferritin and hair iron levels were analyzed for differences using the Mann-Whitney U test. Their correlations with hair diameter and density were assessed using the Spearman correlation test. Serum ferritin (AGA vs. control, median: 222 vs. 232 ng/mL; p=0.758) and total hair iron levels (22.65 vs. 39.67 ng/mL; p=0.102) showed no significant differences between the groups. However, in men with milder AGA (grade <4), total hair iron level and hair diameter showed significant weak positive correlations (r=0.312, p=0.033). In the non-alopecia group, serum ferritin and total hair iron levels showed a significant weak negative correlation (r=-0.387, p=0.026). Hair iron levels were positively correlated with hair diameter in men with early AGA, suggesting a potential role in promoting hair thickness and highlighting its promise as a target for adjuvant therapy.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147364388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Melanoma risk awareness and sun-protective behavior: Does the sun only hurt on the beach? A cross-sectional survey on 1288 families of a Mediterranean population.","authors":"Vincenzo De Giorgi, Aurora Gaeta, Federico Venturi, Elisabetta Magnaterra, Gian Marco Tomassini, Stefano Borgognoni, Biancamaria Zuccaro, Gabriella Perillo, Giovanni Cecchi, Federica Fazzari, Sara Gandini, Piero Covarelli","doi":"10.4081/dr.2026.10600","DOIUrl":"https://doi.org/10.4081/dr.2026.10600","url":null,"abstract":"<p><p>Most of the literature describing sun protection for children is based on population surveys and questionnaires, and these have shown that parents have considerable knowledge about sun exposure, its correlation with skin cancer, and proper protection. We conducted research to evaluate the habits not of the individual but of the families and the degree to which children and their parents understand sun protection and sun exposure. A cross-sectional descriptive study included the parents of children aged 8 to 10 years attending primary schools. Each student was given a simple questionnaire by the teacher and was instructed to take it to their parents for completion. The questions addressed the type and duration of vacation, knowledge of damage that can be caused by sun exposure, and the use of sun protection devices both in the city and in other situations. Of the 2,985 distributed questionnaires, 1,288 were returned, resulting in a final sample of 1,288 families included in the analysis. Most families reported taking either one week (44%) or two weeks (41%) of holiday. During holidays, 53% stated that they applied sunscreen more than once per day on days with typical sun exposure; however, 72% reported adopting no additional preventive measures during outdoor activities. Considering that most families take no more than two weeks of holiday per year, they remain without adequate protection during outdoor activities for approximately 97% of the year. This suggests a need for more targeted education and awareness campaigns, emphasizing the importance of sun protection measures in various settings, including urban environments and year-round activities.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147354155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protective effect of Cavilon™ on radiodermatitis in breast cancer patients undergoing radiotherapy.","authors":"Paula De Paula Casotti, Sérgio Gomes da Silva, Ulisses De Barros Ramos, Breno Jorge Silveira, Fabrizio Dos Santos Cardoso, Ana Carolina Ribeiro de Oliveira, Marcos Luiz Bezerra Junior, Rodrigo Bastos Tostes","doi":"10.4081/dr.2026.10026","DOIUrl":"https://doi.org/10.4081/dr.2026.10026","url":null,"abstract":"<p><p>Radiodermatitis is a common problem in breast cancer treatment with ionizing radiation. It may result in interruption of radiotherapy, depending on the level of the skin lesion. Therefore, the present study aimed to evaluate the efficacy of Cavilon™ (3M, St. Paul, MN, USA), a novel prophylactic agent, in preventing mammary radiodermatitis compared to conventional sunflower oil. This prospective study involved 19 breast cancer patients receiving radiotherapy. Participants received Cavilon™ on one breast quadrant and sunflower oil on the opposite quadrant. The occurrence and severity of radiodermatitis were assessed twice weekly over 25 treatment sessions. Post-treatment assessments indicated that 16% of the Cavilon™-treated quadrants exhibited no radiodermatitis (stage 0), compared to 11% in the sunflower oil-treated quadrants. The mean degree of radiodermatitis was 0.95 (95% confidence interval [CI]: 0.61-1.29) with Cavilon™ vs. 1.37 (95% CI: 0.97-1.77) with sunflower oil, a statistically significant difference (paired t-test: p=0.016; Wilcoxon signed-rank test: p=0.021). Progression to stage 3 occurred in 5% of Cavilon™-treated quadrants vs. 11% with sunflower oil. The findings suggest that Cavilon™ is more effective than sunflower oil in mitigating the progression of radiodermatitis in breast cancer patients undergoing radiotherapy. Its application is a beneficial addition to the skin management protocol in radiation oncology.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147303272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}